Does this specific device model hold a current medical device licence or registration in my target market?

For Canada: ask for the Health Canada MDL number and verify it on MDALL. For Australia: the ARTG entry number, verifiable on the TGA website. For the US: FDA 510(k) clearance number. For the EU: CE certificate and notified body name under EU MDR. Request the actual licence document — not a summary, not a marketing statement. A device without a current, active, market-specific licence cannot be legally sold in that market. If the supplier says "it is in process," ask for the specific submission reference and a realistic timeline, and do not proceed without confirmed regulatory status unless you have legal advice confirming a valid exemption applies. Red flag: supplier cannot produce a licence document or gives a vague "globally compliant" answer.

What regulatory classification does the device hold, and what is the scope of the intended use on the licence?

Classification determines the regulatory pathway and the level of pre-market scrutiny the device underwent. In Canada, Class II BIA devices have lower pre-market requirements than Class III devices. More importantly, the intended use stated on the licence may be narrower than the full clinical use you plan — for example, a device licensed for "body-composition assessment in healthy adults" may not cover use in elderly or clinically ill patients. Check the intended use statement carefully. Red flag: supplier does not know the device's classification or intended-use scope.

Is the manufacturer certified to ISO 13485, and can you provide the current certificate including the certified scope?

ISO 13485 is the international quality management system standard for medical device manufacturers. The certificate should be current (not expired), issued by an accredited certification body (verify the certification body's accreditation through the International Accreditation Forum or the relevant national accreditation body), and the certified scope should explicitly cover design and manufacture of the device category being purchased. A certificate covering "distribution" only, without design and manufacture, provides much weaker assurance. Red flag: certificate is expired, issued by an unaccredited body, or does not cover the relevant device category.

Does the device comply with IEC 60601-1, and what is the applied-part classification?

IEC 60601-1 is the base standard for medical electrical equipment. All clinical BIA devices applying current to patients must comply. The applied-part classification (Type B, BF, or CF) determines the safety context: Type B is for surface contact; Type BF is for body-applied parts with higher protection against stray current; Type CF is for cardiac-floating applications. For aged-care use, Type B or BF is appropriate; Type CF is not typically required unless the device will be used near cardiac monitoring equipment. Request the IEC 60601-1 test report from an accredited laboratory, not just a declaration. Red flag: supplier cannot produce a test report or cites a non-IEC safety standard that is not an equivalent adoption.

Is this a single-frequency or multi-frequency device, and what frequencies does it operate at?

Single-frequency BIA applies current at one frequency (typically 50 kHz) and uses population regression equations. Multi-frequency BIA (BIS) applies current across a range of frequencies and models the Cole-Cole curve to separate extracellular and intracellular water compartments. For aged-care patients with heart failure, chronic kidney disease, or lymphoedema — conditions that cause abnormal fluid distribution — multi-frequency BIA is more accurate and clinically appropriate. Phase angle, a biomarker of cellular integrity and nutritional status, is also more reliably reported from multi-frequency devices. Red flag: supplier describes multi-frequency capability but cannot specify the frequency range or the modelling method.

What are the contraindications for this device, and what patient populations are excluded from use?

All BIA devices apply electrical current and are contraindicated in patients with implanted electronic devices such as pacemakers and implantable cardioverter-defibrillators (ICDs) unless the manufacturer explicitly states the device is safe for use in these patients and provides supporting evidence. In aged-care settings, a significant proportion of residents may have cardiac implants. The device's Instructions for Use (IFU) should state contraindications clearly. Verify that the contraindication list is operationally manageable for your patient population and that your clinical staff will have a protocol for excluded patients. Red flag: supplier is unaware of contraindications or says there are none — all BIA devices applying current have some patient exclusions.

What published validation studies exist for this device in populations aged 65 and above, and what reference method was used?

BIA regression equations are population-specific. A device validated in young athletes or general adults will produce systematic errors in elderly patients with low muscle mass, altered body-water distribution, and chronic disease. Ask the supplier to provide the primary validation publications — not marketing summaries. The validation should have been conducted against a criterion reference method (DXA, four-compartment modelling, or deuterium dilution) in a population representative of your clinical context. EWGSOP2 sarcopenia guidelines accept BIA for muscle mass assessment but require device- and population-specific validation to be considered. Red flag: supplier provides only general population validation or cannot cite a peer-reviewed publication.

Is there published or documented evidence that this device's outputs are compatible with MUST, MNA-SF, or EWGSOP2 sarcopenia screening workflows?

MUST (Malnutrition Universal Screening Tool) and MNA-SF (Mini Nutritional Assessment Short Form) are the two most widely used malnutrition screening instruments in hospital and aged-care settings. EWGSOP2 is the standard framework for sarcopenia diagnosis. A reputable clinical BIA supplier will be able to explain how the device's outputs — skeletal muscle index, fat-free mass, phase angle — map onto the decision points in these workflows, and ideally cite clinical sites or publications demonstrating integration. This question also reveals whether the supplier has genuine clinical expertise in aged-care nutrition or is primarily a technology vendor. Red flag: supplier is unfamiliar with MUST, MNA-SF, or EWGSOP2.

Who is the in-country service entity, what is the calibration requirement and interval, and what are the response-time commitments for service calls?

Clinical devices require ongoing maintenance. For BIA analyzers, this typically includes periodic verification against calibration standards and software updates. Verify that the entity providing in-country service has qualified biomedical engineers (not just general IT support), that calibration procedures are documented and traceable, and that service-level agreements are included in the contract. For multi-site aged-care operators procuring fleet quantities, the service model must scale to the number of devices and geographic distribution of facilities. Confirm parts availability and whether the device will be supported for the expected operational lifecycle (typically five to seven years). Red flag: service is provided by the overseas manufacturer with no local entity, or calibration requirements are undefined.

How are software updates delivered, are they free, and does a software update that changes body-composition algorithms require regulatory notification?

BIA software updates can be clinically significant. A change to the regression equations used to calculate fat mass or skeletal muscle mass changes the device's outputs — meaning longitudinal data collected before and after the update may not be comparable. For clinical programs using BIA to monitor nutritional intervention response over months or years, algorithm changes can undermine the validity of the monitoring data. Ask specifically whether the supplier notifies customers when an update changes a clinical algorithm, and whether such changes are reported to the relevant regulatory authority. Under regulations like Health Canada's Medical Devices Regulations, significant changes to a licensed device may require a licence amendment. Red flag: supplier has no policy on algorithm change notification or treats all software updates as equivalent.

Has this device ever been subject to a field safety corrective action (recall or advisory), and what is the process for communicating future regulatory actions to customers?

A history of field safety corrective actions is not automatically disqualifying — it can indicate a manufacturer with mature post-market surveillance that identifies and addresses problems. The relevant question is: were the issues identified promptly, was the response adequate, and was the communication to customers timely and clear? For future actions, the supplier should be able to describe their regulatory affairs process for field safety corrective actions, including how they notify the regulator, how they notify customers, and how they track remediation. This information should be part of the supply contract. Red flag: supplier is unaware of any past corrective actions on a device with a multi-year market history, or cannot describe their regulatory affairs process.

What data export formats does the device support, and can it integrate with our electronic health record system?

For aged-care and hospital procurement at scale, data management is an operational cost factor. A device that produces PDF reports only — requiring manual transcription into the EHR — creates nursing documentation burden and introduces transcription error. Ask specifically whether the device can export structured data in CSV, HL7, or FHIR format, and whether the supplier has an existing integration or API for your EHR system. For multi-site operators, also ask whether measurement data can be aggregated centrally for governance and quality reporting. These are not regulatory requirements, but they are operationally material for clinical informatics and care pathway integration. Red flag: supplier has no structured data export capability and no roadmap for EHR integration.